BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 270 filers reported holding BIO-TECHNE CORP in Q1 2017. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $436,000 | -7.4% | 900 | -52.6% | 0.03% | 0.0% |
| Q3 2020 | $471,000 | -94.0% | 1,900 | -95.4% | 0.03% | -95.0% |
| Q1 2020 | $7,888,000 | -16.1% | 41,600 | -2.9% | 0.62% | +7.8% |
| Q4 2019 | $9,400,000 | +17.2% | 42,824 | +4.4% | 0.58% | +21.8% |
| Q3 2019 | $8,022,000 | -12.0% | 41,000 | -6.2% | 0.48% | -11.7% |
| Q2 2019 | $9,112,000 | -9.5% | 43,706 | -13.8% | 0.54% | -5.3% |
| Q1 2019 | $10,066,000 | +23.3% | 50,700 | -10.1% | 0.57% | +24.8% |
| Q4 2018 | $8,162,000 | -37.0% | 56,400 | -11.2% | 0.46% | -15.2% |
| Q3 2018 | $12,963,000 | +38.0% | 63,512 | +0.0% | 0.54% | +50.7% |
| Q2 2018 | $9,395,000 | -2.0% | 63,500 | 0.0% | 0.36% | +10.2% |
| Q1 2018 | $9,591,000 | +225.0% | 63,500 | +121.3% | 0.32% | +67.9% |
| Q4 2016 | $2,951,000 | -6.8% | 28,700 | -0.7% | 0.19% | +4.3% |
| Q3 2016 | $3,165,000 | -2.2% | 28,900 | +0.7% | 0.18% | -27.7% |
| Q2 2016 | $3,236,000 | +19.3% | 28,700 | 0.0% | 0.26% | +50.6% |
| Q1 2016 | $2,713,000 | +343.3% | 28,700 | +361.9% | 0.17% | +962.5% |
| Q2 2015 | $612,000 | – | 6,213 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ROWLANDMILLER & PARTNERS.ADV | 47,975 | $3,701,751 | 0.85% |
| Diversified Trust Co | 13,882 | $1,071,135 | 0.04% |
| Czech National Bank | 27,698 | $2,137,178 | 0.03% |
| FULTON BANK, N.A. | 5,444 | $420,058 | 0.02% |
| DnB Asset Management AS | 27,637 | $2,132,471 | 0.01% |
| Versant Capital Management, Inc | 36 | $2,778 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 371 | $28,626 | 0.00% |
| Bartlett & Co. LLC | 172 | $13 | 0.00% |